 David Pitrak
Concepts (374)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 29 | 2021 | 727 | 4.470 |
Why?
| | AIDS Serodiagnosis | 5 | 2020 | 29 | 2.150 |
Why?
| | Lyme Disease | 2 | 2022 | 11 | 1.900 |
Why?
| | Antiretroviral Therapy, Highly Active | 7 | 2020 | 65 | 1.560 |
Why?
| | Mass Screening | 7 | 2021 | 626 | 1.540 |
Why?
| | HIV Seropositivity | 12 | 2020 | 72 | 1.520 |
Why?
| | Continuity of Patient Care | 5 | 2020 | 180 | 1.470 |
Why?
| | Practice Guidelines as Topic | 3 | 2022 | 1088 | 1.430 |
Why?
| | Neutrophils | 8 | 2010 | 292 | 1.340 |
Why?
| | HIV-1 | 10 | 2014 | 163 | 1.330 |
Why?
| | HIV | 4 | 2021 | 44 | 1.180 |
Why?
| | Hospitals, Urban | 3 | 2021 | 63 | 1.140 |
Why?
| | Anti-HIV Agents | 6 | 2020 | 148 | 1.130 |
Why?
| | Emergency Service, Hospital | 4 | 2021 | 443 | 1.110 |
Why?
| | Anti-Bacterial Agents | 2 | 2022 | 825 | 0.960 |
Why?
| | Borrelia burgdorferi | 1 | 2022 | 6 | 0.950 |
Why?
| | Antibodies, Bacterial | 1 | 2022 | 96 | 0.910 |
Why?
| | Antibiotic Prophylaxis | 1 | 2022 | 81 | 0.890 |
Why?
| | Granulocyte Colony-Stimulating Factor | 6 | 2003 | 167 | 0.850 |
Why?
| | Immunoglobulin G | 4 | 2019 | 483 | 0.840 |
Why?
| | Respiratory Tract Infections | 2 | 2018 | 101 | 0.820 |
Why?
| | Pyrimidinones | 2 | 2010 | 33 | 0.810 |
Why?
| | Organ Transplantation | 2 | 2019 | 281 | 0.800 |
Why?
| | Agammaglobulinemia | 1 | 2019 | 21 | 0.800 |
Why?
| | Bordetella Infections | 1 | 2018 | 6 | 0.770 |
Why?
| | Medical Informatics | 1 | 2019 | 41 | 0.760 |
Why?
| | Diagnostic Errors | 1 | 2018 | 169 | 0.680 |
Why?
| | CD4 Lymphocyte Count | 9 | 2020 | 75 | 0.670 |
Why?
| | Antibodies, Viral | 1 | 2019 | 345 | 0.670 |
Why?
| | Chicago | 14 | 2020 | 1455 | 0.670 |
Why?
| | Pandemics | 2 | 2021 | 559 | 0.640 |
Why?
| | Phagocytes | 3 | 2003 | 15 | 0.640 |
Why?
| | Acquired Immunodeficiency Syndrome | 4 | 1999 | 86 | 0.630 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 220 | 0.630 |
Why?
| | Apoptosis | 5 | 2014 | 1782 | 0.620 |
Why?
| | Bone Marrow Transplantation | 2 | 2010 | 293 | 0.610 |
Why?
| | Adult | 42 | 2022 | 26137 | 0.600 |
Why?
| | Respiratory Burst | 5 | 2003 | 23 | 0.590 |
Why?
| | Humans | 71 | 2022 | 84199 | 0.570 |
Why?
| | Point-of-Care Systems | 1 | 2016 | 134 | 0.570 |
Why?
| | Anti-Retroviral Agents | 1 | 2014 | 27 | 0.560 |
Why?
| | Calcitonin | 1 | 2013 | 44 | 0.530 |
Why?
| | African Americans | 3 | 2020 | 1171 | 0.530 |
Why?
| | Protein Precursors | 1 | 2013 | 148 | 0.500 |
Why?
| | T-Lymphocyte Subsets | 1 | 2014 | 301 | 0.470 |
Why?
| | Male | 45 | 2020 | 42140 | 0.460 |
Why?
| | Bacterial Infections | 4 | 2020 | 227 | 0.460 |
Why?
| | Middle Aged | 33 | 2020 | 25702 | 0.450 |
Why?
| | Female | 41 | 2020 | 45032 | 0.440 |
Why?
| | Ritonavir | 1 | 2010 | 14 | 0.440 |
Why?
| | Opportunistic Infections | 2 | 2008 | 68 | 0.410 |
Why?
| | Sepsis | 4 | 2016 | 303 | 0.410 |
Why?
| | Mycoses | 4 | 2020 | 60 | 0.390 |
Why?
| | Benzoxazines | 1 | 2009 | 11 | 0.390 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2009 | 21 | 0.390 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 532 | 0.380 |
Why?
| | Rural Health | 1 | 2007 | 22 | 0.350 |
Why?
| | Physicians | 1 | 2014 | 611 | 0.340 |
Why?
| | Antifungal Agents | 2 | 2010 | 141 | 0.340 |
Why?
| | C-Reactive Protein | 1 | 2008 | 194 | 0.330 |
Why?
| | Risk Factors | 8 | 2022 | 5454 | 0.300 |
Why?
| | Sexual Behavior | 1 | 2007 | 281 | 0.280 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2010 | 401 | 0.270 |
Why?
| | Communicable Diseases, Emerging | 1 | 2003 | 13 | 0.260 |
Why?
| | West Nile Fever | 1 | 2003 | 24 | 0.260 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2010 | 825 | 0.260 |
Why?
| | Disease Outbreaks | 2 | 2003 | 190 | 0.250 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 1774 | 0.240 |
Why?
| | Fungi | 1 | 2003 | 71 | 0.240 |
Why?
| | Doxycycline | 1 | 2022 | 33 | 0.240 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2008 | 673 | 0.240 |
Why?
| | Hematologic Neoplasms | 2 | 2016 | 295 | 0.240 |
Why?
| | Child | 3 | 2022 | 6847 | 0.230 |
Why?
| | Asymptomatic Diseases | 1 | 2022 | 41 | 0.230 |
Why?
| | Population Surveillance | 1 | 2003 | 241 | 0.230 |
Why?
| | Retrospective Studies | 15 | 2021 | 7798 | 0.230 |
Why?
| | Neutropenia | 2 | 1999 | 223 | 0.230 |
Why?
| | Coinfection | 1 | 2021 | 41 | 0.220 |
Why?
| | Immunocompromised Host | 2 | 2018 | 144 | 0.220 |
Why?
| | Substance-Related Disorders | 5 | 2007 | 387 | 0.210 |
Why?
| | Contact Tracing | 1 | 2020 | 32 | 0.210 |
Why?
| | Lopinavir | 2 | 2010 | 8 | 0.210 |
Why?
| | Viral Load | 3 | 2020 | 143 | 0.210 |
Why?
| | Capsaicin | 1 | 2000 | 47 | 0.210 |
Why?
| | Tetanus Toxoid | 1 | 2019 | 14 | 0.200 |
Why?
| | Intensive Care Units | 2 | 2016 | 374 | 0.200 |
Why?
| | Measles virus | 1 | 2019 | 17 | 0.200 |
Why?
| | Sexual Partners | 1 | 2020 | 95 | 0.200 |
Why?
| | Health Plan Implementation | 1 | 2020 | 61 | 0.200 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 155 | 0.190 |
Why?
| | Social Networking | 2 | 2020 | 74 | 0.190 |
Why?
| | Bordetella bronchiseptica | 1 | 2018 | 7 | 0.190 |
Why?
| | Academic Medical Centers | 2 | 2020 | 395 | 0.190 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2000 | 87 | 0.190 |
Why?
| | Bordetella pertussis | 1 | 2018 | 18 | 0.190 |
Why?
| | Incidence | 3 | 2019 | 1652 | 0.190 |
Why?
| | HIV Seroprevalence | 1 | 2018 | 13 | 0.190 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2018 | 36 | 0.190 |
Why?
| | Seroepidemiologic Studies | 1 | 2018 | 55 | 0.190 |
Why?
| | Cross Reactions | 1 | 2018 | 135 | 0.190 |
Why?
| | False Positive Reactions | 1 | 2018 | 227 | 0.180 |
Why?
| | Comorbidity | 2 | 2021 | 943 | 0.180 |
Why?
| | Memory Disorders | 3 | 2007 | 65 | 0.180 |
Why?
| | Adolescent | 9 | 2016 | 9210 | 0.180 |
Why?
| | Diagnosis, Differential | 2 | 2022 | 1611 | 0.170 |
Why?
| | DNA, Bacterial | 1 | 2018 | 272 | 0.170 |
Why?
| | Blood Bactericidal Activity | 1 | 1997 | 6 | 0.170 |
Why?
| | Referral and Consultation | 1 | 2020 | 326 | 0.170 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1997 | 108 | 0.170 |
Why?
| | Homosexuality, Male | 3 | 2020 | 271 | 0.170 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2013 | 868 | 0.170 |
Why?
| | Treatment Outcome | 5 | 2020 | 7966 | 0.160 |
Why?
| | Recombinant Proteins | 6 | 2003 | 1067 | 0.160 |
Why?
| | RNA, Viral | 3 | 2010 | 345 | 0.160 |
Why?
| | Antineoplastic Agents | 1 | 2008 | 2373 | 0.150 |
Why?
| | Marijuana Smoking | 1 | 2016 | 43 | 0.150 |
Why?
| | Young Adult | 6 | 2020 | 6007 | 0.150 |
Why?
| | Reactive Oxygen Species | 1 | 1998 | 461 | 0.150 |
Why?
| | Clinical Laboratory Techniques | 1 | 2016 | 81 | 0.150 |
Why?
| | Sex Factors | 2 | 2018 | 1095 | 0.150 |
Why?
| | Propidium | 1 | 2014 | 9 | 0.150 |
Why?
| | Neoplasms | 1 | 2010 | 2725 | 0.140 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 32 | 0.140 |
Why?
| | Luminescent Measurements | 3 | 1999 | 62 | 0.140 |
Why?
| | AIDS Dementia Complex | 3 | 2001 | 13 | 0.140 |
Why?
| | Coronavirus Infections | 1 | 2020 | 289 | 0.140 |
Why?
| | Delivery of Health Care | 1 | 2018 | 318 | 0.140 |
Why?
| | Caspases | 1 | 2014 | 170 | 0.140 |
Why?
| | Staining and Labeling | 1 | 2014 | 187 | 0.140 |
Why?
| | Common Variable Immunodeficiency | 1 | 2013 | 4 | 0.130 |
Why?
| | Cross-Sectional Studies | 3 | 2016 | 1452 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 947 | 0.130 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2013 | 35 | 0.130 |
Why?
| | Interferon-alpha | 3 | 2002 | 240 | 0.130 |
Why?
| | Cytomegalovirus Infections | 2 | 2013 | 158 | 0.130 |
Why?
| | Daptomycin | 1 | 2013 | 5 | 0.130 |
Why?
| | Minocycline | 1 | 2013 | 18 | 0.130 |
Why?
| | Superoxides | 1 | 1993 | 83 | 0.130 |
Why?
| | Edetic Acid | 1 | 2013 | 46 | 0.130 |
Why?
| | Biofilms | 1 | 2013 | 44 | 0.120 |
Why?
| | Drug Therapy, Combination | 4 | 2010 | 994 | 0.120 |
Why?
| | Glycoproteins | 1 | 2013 | 253 | 0.120 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 90 | 0.120 |
Why?
| | Prospective Studies | 2 | 2019 | 4122 | 0.110 |
Why?
| | Mental Recall | 2 | 2007 | 128 | 0.110 |
Why?
| | Drug Resistance, Fungal | 1 | 2010 | 6 | 0.110 |
Why?
| | Fluconazole | 1 | 2010 | 16 | 0.110 |
Why?
| | Candida | 1 | 2010 | 21 | 0.110 |
Why?
| | Fungemia | 1 | 2010 | 24 | 0.110 |
Why?
| | Gram-Negative Aerobic Bacteria | 1 | 2010 | 5 | 0.110 |
Why?
| | Candidiasis | 1 | 2010 | 37 | 0.100 |
Why?
| | Psychomotor Performance | 4 | 2003 | 509 | 0.100 |
Why?
| | Algorithms | 1 | 2019 | 1854 | 0.100 |
Why?
| | Vibrio Infections | 1 | 1989 | 3 | 0.100 |
Why?
| | Lymphopenia | 1 | 2010 | 31 | 0.100 |
Why?
| | Vibrio cholerae | 1 | 1989 | 25 | 0.100 |
Why?
| | Water Microbiology | 1 | 1989 | 17 | 0.100 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2010 | 32 | 0.100 |
Why?
| | Cellulitis | 1 | 1989 | 22 | 0.100 |
Why?
| | Lymphocyte Subsets | 1 | 2010 | 69 | 0.100 |
Why?
| | Ethanol | 1 | 2013 | 304 | 0.100 |
Why?
| | Blastomycosis | 1 | 1989 | 8 | 0.100 |
Why?
| | AIDS-Related Opportunistic Infections | 3 | 2000 | 42 | 0.100 |
Why?
| | Cognition | 3 | 2004 | 505 | 0.100 |
Why?
| | Enterococcus | 2 | 2009 | 61 | 0.100 |
Why?
| | Aged | 5 | 2020 | 18611 | 0.100 |
Why?
| | Ketoconazole | 1 | 1989 | 33 | 0.100 |
Why?
| | Lung Diseases, Fungal | 1 | 1989 | 27 | 0.100 |
Why?
| | Cyclopropanes | 1 | 2009 | 29 | 0.100 |
Why?
| | Alkynes | 1 | 2009 | 20 | 0.100 |
Why?
| | Odds Ratio | 2 | 2010 | 684 | 0.100 |
Why?
| | Age Factors | 2 | 2016 | 1923 | 0.100 |
Why?
| | Phialophora | 1 | 1988 | 2 | 0.100 |
Why?
| | Foot Dermatoses | 1 | 1988 | 4 | 0.100 |
Why?
| | Anti-Infective Agents | 1 | 2010 | 109 | 0.100 |
Why?
| | Sarcoidosis | 1 | 2010 | 91 | 0.100 |
Why?
| | Drug Resistance, Viral | 1 | 2009 | 54 | 0.100 |
Why?
| | Drug Resistance, Bacterial | 1 | 2009 | 80 | 0.100 |
Why?
| | Attention | 2 | 2007 | 371 | 0.090 |
Why?
| | Hepatitis C | 3 | 1997 | 209 | 0.090 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2009 | 163 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2011 | 279 | 0.090 |
Why?
| | Brain Diseases | 1 | 1989 | 188 | 0.090 |
Why?
| | Prevalence | 4 | 2016 | 1272 | 0.090 |
Why?
| | Chemotaxis, Leukocyte | 2 | 1998 | 39 | 0.090 |
Why?
| | Reaction Time | 2 | 1999 | 316 | 0.090 |
Why?
| | Analysis of Variance | 3 | 2007 | 965 | 0.080 |
Why?
| | India | 1 | 2007 | 140 | 0.080 |
Why?
| | Health Services Research | 1 | 2008 | 139 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2009 | 973 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2010 | 518 | 0.080 |
Why?
| | Severity of Illness Index | 4 | 2016 | 1784 | 0.080 |
Why?
| | Vancomycin Resistance | 1 | 2006 | 37 | 0.080 |
Why?
| | Bacteria | 1 | 2009 | 465 | 0.070 |
Why?
| | HIV Seronegativity | 2 | 2003 | 16 | 0.070 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2006 | 66 | 0.070 |
Why?
| | Liver Transplantation | 1 | 2013 | 1251 | 0.070 |
Why?
| | Neuropsychological Tests | 6 | 2007 | 449 | 0.070 |
Why?
| | Hospitalization | 3 | 2021 | 778 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2007 | 1833 | 0.070 |
Why?
| | Antiviral Agents | 2 | 2020 | 507 | 0.070 |
Why?
| | Memory, Short-Term | 3 | 2004 | 205 | 0.070 |
Why?
| | Luminol | 1 | 2003 | 4 | 0.060 |
Why?
| | Flow Cytometry | 3 | 2010 | 728 | 0.060 |
Why?
| | International Classification of Diseases | 1 | 2003 | 66 | 0.060 |
Why?
| | Mitogens | 2 | 2000 | 67 | 0.060 |
Why?
| | Inpatients | 2 | 2020 | 277 | 0.060 |
Why?
| | Complement System Proteins | 2 | 1999 | 91 | 0.060 |
Why?
| | Transplantation, Autologous | 1 | 2003 | 337 | 0.060 |
Why?
| | Logistic Models | 3 | 2016 | 1166 | 0.060 |
Why?
| | Follow-Up Studies | 2 | 2013 | 3883 | 0.050 |
Why?
| | Needle Sharing | 1 | 2020 | 14 | 0.050 |
Why?
| | Impulsive Behavior | 1 | 2004 | 264 | 0.050 |
Why?
| | Risk-Taking | 2 | 2016 | 167 | 0.050 |
Why?
| | Verbal Learning | 1 | 2000 | 29 | 0.050 |
Why?
| | Biomarkers, Pharmacological | 1 | 2020 | 24 | 0.050 |
Why?
| | Azithromycin | 1 | 2020 | 17 | 0.050 |
Why?
| | Hydroxychloroquine | 1 | 2020 | 15 | 0.050 |
Why?
| | Transplantation, Homologous | 1 | 2003 | 1022 | 0.050 |
Why?
| | Cephalosporins | 1 | 2020 | 42 | 0.050 |
Why?
| | Serologic Tests | 1 | 2020 | 45 | 0.050 |
Why?
| | Mycobacterium avium Complex | 1 | 2000 | 9 | 0.050 |
Why?
| | Administration, Topical | 1 | 2000 | 98 | 0.050 |
Why?
| | Auditory Perception | 1 | 2001 | 94 | 0.050 |
Why?
| | Acute Disease | 2 | 2020 | 869 | 0.050 |
Why?
| | Tuberculosis, Multidrug-Resistant | 1 | 1999 | 3 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2020 | 6605 | 0.050 |
Why?
| | Pneumonia, Pneumocystis | 2 | 1999 | 23 | 0.050 |
Why?
| | Risk Assessment | 1 | 2008 | 2295 | 0.050 |
Why?
| | Leukocyte Count | 2 | 1997 | 225 | 0.050 |
Why?
| | Ambulatory Care Facilities | 1 | 2020 | 92 | 0.050 |
Why?
| | Cohort Studies | 2 | 2014 | 2731 | 0.050 |
Why?
| | Peroxidase | 1 | 1999 | 60 | 0.050 |
Why?
| | Treatment Failure | 1 | 2000 | 303 | 0.050 |
Why?
| | Antigens, Bacterial | 1 | 2000 | 137 | 0.050 |
Why?
| | Platelet Activating Factor | 1 | 1999 | 71 | 0.050 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 411 | 0.050 |
Why?
| | Hepatitis Antibodies | 2 | 1994 | 8 | 0.040 |
Why?
| | Liposomes | 1 | 1998 | 104 | 0.040 |
Why?
| | Interleukin-2 | 1 | 1998 | 287 | 0.040 |
Why?
| | Palliative Care | 1 | 2000 | 255 | 0.040 |
Why?
| | Receptors, Immunologic | 1 | 1998 | 165 | 0.040 |
Why?
| | Reference Values | 1 | 1999 | 704 | 0.040 |
Why?
| | Phospholipids | 1 | 1998 | 126 | 0.040 |
Why?
| | Acridine Orange | 1 | 1996 | 3 | 0.040 |
Why?
| | Cross Infection | 1 | 1999 | 193 | 0.040 |
Why?
| | Ethidium | 1 | 1996 | 14 | 0.040 |
Why?
| | Regression Analysis | 2 | 2002 | 628 | 0.040 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1996 | 58 | 0.040 |
Why?
| | Histocytochemistry | 1 | 1996 | 137 | 0.040 |
Why?
| | Cell Size | 1 | 1996 | 69 | 0.040 |
Why?
| | APACHE | 1 | 2016 | 21 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2000 | 813 | 0.040 |
Why?
| | Microscopy, Electron | 1 | 1996 | 534 | 0.040 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2016 | 26 | 0.040 |
Why?
| | Unsafe Sex | 1 | 2016 | 44 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 1997 | 296 | 0.040 |
Why?
| | Diagnostic Tests, Routine | 1 | 2016 | 65 | 0.040 |
Why?
| | Hepatitis, Chronic | 1 | 1994 | 7 | 0.040 |
Why?
| | Program Development | 1 | 2016 | 136 | 0.040 |
Why?
| | Microscopy, Fluorescence | 1 | 1996 | 443 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2000 | 1912 | 0.040 |
Why?
| | Hepatitis E virus | 1 | 1994 | 7 | 0.040 |
Why?
| | Immunity, Innate | 1 | 1999 | 433 | 0.040 |
Why?
| | Hepatitis E | 1 | 1994 | 10 | 0.040 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 315 | 0.040 |
Why?
| | HIV Core Protein p24 | 1 | 1993 | 9 | 0.030 |
Why?
| | Cell Survival | 1 | 1996 | 1016 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 764 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 127 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2016 | 585 | 0.030 |
Why?
| | Length of Stay | 1 | 2016 | 705 | 0.030 |
Why?
| | End Stage Liver Disease | 1 | 2013 | 52 | 0.030 |
Why?
| | Urban Population | 1 | 2014 | 229 | 0.030 |
Why?
| | Drug Combinations | 1 | 2013 | 245 | 0.030 |
Why?
| | Obesity | 2 | 1997 | 975 | 0.030 |
Why?
| | Liver | 2 | 1994 | 1260 | 0.030 |
Why?
| | Child, Preschool | 1 | 1999 | 3788 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2013 | 875 | 0.030 |
Why?
| | Erythromycin | 1 | 1990 | 14 | 0.030 |
Why?
| | Vagotomy | 1 | 1990 | 12 | 0.030 |
Why?
| | Piperacillin | 1 | 2010 | 10 | 0.030 |
Why?
| | Quality of Health Care | 2 | 2008 | 367 | 0.030 |
Why?
| | Penicillanic Acid | 1 | 2010 | 14 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 902 | 0.030 |
Why?
| | Gastric Emptying | 1 | 1990 | 24 | 0.030 |
Why?
| | Stomach Diseases | 1 | 1990 | 23 | 0.030 |
Why?
| | Gastrointestinal Motility | 1 | 1990 | 32 | 0.030 |
Why?
| | DNA | 1 | 1996 | 1307 | 0.030 |
Why?
| | Phenotype | 1 | 1997 | 2320 | 0.030 |
Why?
| | Ciprofloxacin | 1 | 2010 | 56 | 0.030 |
Why?
| | Antigens, CD19 | 1 | 2010 | 35 | 0.030 |
Why?
| | Fresh Water | 1 | 1989 | 25 | 0.030 |
Why?
| | Klebsiella | 1 | 2009 | 7 | 0.030 |
Why?
| | Animals | 1 | 2010 | 27167 | 0.030 |
Why?
| | Maryland | 1 | 2009 | 30 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2010 | 99 | 0.030 |
Why?
| | Survival Analysis | 1 | 2014 | 1591 | 0.030 |
Why?
| | Pseudomonas | 1 | 2009 | 52 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2010 | 218 | 0.020 |
Why?
| | Zidovudine | 2 | 1999 | 20 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 1989 | 268 | 0.020 |
Why?
| | Illinois | 1 | 1989 | 473 | 0.020 |
Why?
| | Prognosis | 1 | 2016 | 3729 | 0.020 |
Why?
| | Health Services | 1 | 2008 | 55 | 0.020 |
Why?
| | Kidney Transplantation | 1 | 1994 | 835 | 0.020 |
Why?
| | Hospitals, University | 1 | 2008 | 205 | 0.020 |
Why?
| | Hospitals | 1 | 2009 | 212 | 0.020 |
Why?
| | Administration, Oral | 1 | 1989 | 729 | 0.020 |
Why?
| | Graft Rejection | 1 | 2013 | 1112 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2007 | 380 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2000 | 411 | 0.020 |
Why?
| | Escherichia coli | 1 | 2009 | 627 | 0.020 |
Why?
| | Staphylococcus aureus | 1 | 2009 | 293 | 0.020 |
Why?
| | Carrier State | 1 | 2006 | 57 | 0.020 |
Why?
| | Substance Abuse, Intravenous | 2 | 1995 | 49 | 0.020 |
Why?
| | Substance Abuse Detection | 1 | 2004 | 14 | 0.020 |
Why?
| | Alanine Transaminase | 2 | 1994 | 79 | 0.020 |
Why?
| | Psychological Tests | 1 | 2004 | 93 | 0.020 |
Why?
| | Hepacivirus | 2 | 1997 | 152 | 0.020 |
Why?
| | Chronic Disease | 2 | 1997 | 978 | 0.010 |
Why?
| | Alcohol Drinking | 1 | 2004 | 275 | 0.010 |
Why?
| | Phytohemagglutinins | 1 | 2000 | 24 | 0.010 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2000 | 7 | 0.010 |
Why?
| | Zalcitabine | 1 | 1999 | 4 | 0.010 |
Why?
| | Didanosine | 1 | 1999 | 4 | 0.010 |
Why?
| | CD4-CD8 Ratio | 1 | 1999 | 22 | 0.010 |
Why?
| | Prefrontal Cortex | 1 | 2001 | 113 | 0.010 |
Why?
| | Postoperative Complications | 1 | 1990 | 2280 | 0.010 |
Why?
| | Time Factors | 1 | 1989 | 5516 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 1999 | 326 | 0.010 |
Why?
| | Enterotoxins | 1 | 1998 | 22 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 1989 | 2585 | 0.010 |
Why?
| | Brain | 1 | 1989 | 2165 | 0.010 |
Why?
| | Zymosan | 1 | 1998 | 12 | 0.010 |
Why?
| | Opsonin Proteins | 1 | 1998 | 8 | 0.010 |
Why?
| | Vasoactive Intestinal Peptide | 1 | 1998 | 18 | 0.010 |
Why?
| | Phosphatidylethanolamines | 1 | 1998 | 24 | 0.010 |
Why?
| | Problem Solving | 1 | 1998 | 53 | 0.010 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 1 | 1998 | 40 | 0.010 |
Why?
| | Choice Behavior | 1 | 1999 | 161 | 0.010 |
Why?
| | Interleukin-4 | 1 | 1998 | 139 | 0.010 |
Why?
| | Drug Stability | 1 | 1998 | 69 | 0.010 |
Why?
| | Psychiatric Status Rating Scales | 1 | 1999 | 477 | 0.010 |
Why?
| | Lymphocytes | 1 | 2000 | 479 | 0.010 |
Why?
| | 2',5'-Oligoadenylate Synthetase | 1 | 1997 | 10 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 1998 | 278 | 0.010 |
Why?
| | Depression | 1 | 2001 | 416 | 0.010 |
Why?
| | Pilot Projects | 1 | 1999 | 838 | 0.010 |
Why?
| | Leukocytes, Mononuclear | 1 | 1997 | 201 | 0.010 |
Why?
| | Los Angeles | 1 | 1995 | 28 | 0.010 |
Why?
| | Florida | 1 | 1995 | 55 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 1998 | 393 | 0.010 |
Why?
| | Hepatitis C Antibodies | 1 | 1994 | 9 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 1994 | 72 | 0.010 |
Why?
| | Liver Function Tests | 1 | 1994 | 99 | 0.010 |
Why?
| | Bilirubin | 1 | 1994 | 129 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 1994 | 172 | 0.010 |
Why?
| | Psychometrics | 1 | 1995 | 296 | 0.010 |
Why?
| | Immunoenzyme Techniques | 1 | 1994 | 332 | 0.010 |
Why?
| | Bronchoscopy | 1 | 1995 | 151 | 0.010 |
Why?
| | Disease Progression | 1 | 1998 | 1481 | 0.010 |
Why?
| | Solubility | 1 | 1993 | 213 | 0.010 |
Why?
| | Body Weight | 1 | 1994 | 504 | 0.010 |
Why?
| | Virus Replication | 1 | 1993 | 335 | 0.010 |
Why?
| | Technetium Tc 99m Sulfur Colloid | 1 | 1990 | 11 | 0.010 |
Why?
| | Survival Rate | 1 | 1995 | 1925 | 0.010 |
Why?
| | Biopsy | 1 | 1994 | 1189 | 0.010 |
Why?
| | Renal Dialysis | 1 | 1994 | 385 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1994 | 2104 | 0.010 |
Why?
| | Radionuclide Imaging | 1 | 1990 | 236 | 0.010 |
Why?
| | Stomach | 1 | 1990 | 123 | 0.010 |
Why?
| | Kidney Failure, Chronic | 1 | 1994 | 520 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 1995 | 2685 | 0.010 |
Why?
|
|
Pitrak's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|